RxDoctor Payments Data

Malladi Sastry, MD

Critical Care Medicine · Plano, TXNPI 1275615098

Payments from drug & device makers

$3,758in general payments, 2019–2025

Across 209 payments — averaging $17.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$497
  • Baxter Healthcare$324
  • Philips North America LLC$272
  • Mylan Specialty L.p.$241
  • Sanofi$174
  • plus $1K from 21 others

What the payments were for

  • Food & beverage$3,742100%
  • Education$150%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$3,758 in reported general payments places this provider in the 80th percentile of 507 critical care medicine providers in Texas.

See all critical care medicine providers in Texas

Medicare billing

Part B allowed, 2024
$75,804
Medicare patients
133
Services billed
1,500

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prolastin CAlpha-1-Proteinase Inhibitor12$141,115
Trelegy ElliptaFluticasone/Umeclidin/Vilanter105$77,460
Breo ElliptaFluticasone/Vilanterol47$29,912
Breztri AerosphereBudesonide/Glycopyr/Formoterol31$22,655
SymbicortBudesonide/Formoterol Fumarate48$18,691
Spiriva RespimatTiotropium Bromide19$13,574
Arnuity ElliptaFluticasone Furoate45$8,596
Albuterol Sulfate HfaAlbuterol Sulfate232$6,312
Fluticasone-SalmeterolFluticasone Propion/Salmeterol17$5,230
Advair HfaFluticasone Propion/Salmeterol11$3,524
Wixela InhubFluticasone Propion/Salmeterol14$2,926
Montelukast Sodium198$1,362
Cefdinir43$718
Ventolin HfaAlbuterol Sulfate13$674
Prednisone138$382

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Grifols USA, LLCProlastin C$49$141,11512 claims
GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta$497$115,968197 claims
AstraZenecaBreztri Aerosphere, Symbicort$1,074$41,34679 claims
Boehringer IngelheimSpiriva Respimat$60$13,57419 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 507 critical care medicine providers in Texas.

Other critical care medicine in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →